Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Vesuvius warns on profits as costs mount

(Sharecast News) - Vesuvius warned on Friday that profits were set to fall this year, hit by a softer macroeconomic backdrop and mounting costs. The firm, a specialist in molten metal flow engineering and technology, said trading in the four months to 30 April had been in line with expectations.

Revenues were broadly unchanged, hit by "challenging" end-markets, while trading profits were lower year-on-year, "driven by higher raw material costs and labour cost inflation".

It therefore now expects prices to rise throughout the rest of the year, in part to recover these costs.

Vesuvius said the imposition by Donald Trump of tariffs on the global steel sector had so far not impacted on the business.

But it warned: "However, the macroeconomic environment and a further slowdown in global industrial activity coupled with ongoing softness in our end markets may impact our ability to fully recover all cost inflation.

"We now therefore expect trading profit to be slightly lower than 20204 on a customer currency basis, although the level of uncertainty remains high."

As at 1000 BST, the FTSE 250 stock was down 2% at 368.31p, having earlier fallen as much as 6%.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.